Innovative Stroke Devices Neuravi specializes in advanced neurovascular technologies, notably its EmboTrapII Revascularization Device, which is CE marked and available in Europe. This positions the company as a key player in stroke intervention, offering opportunities to partner on or expand sales of cutting-edge neurovascular equipment in European markets.

Strategic Acquisition Backing Since its acquisition by Johnson & Johnson in April 2017, Neuravi benefits from enhanced global distribution channels, research resources, and credibility, creating potential avenues for upselling existing products or introducing new innovations to J&J’s extensive healthcare network.

Growing R&D Investment With a funding of $17 million and ongoing collaborations aimed at understanding clot dynamics, Neuravi demonstrates a commitment to innovation and product development, suggesting opportunities to engage in joint research initiatives or provide supplementary neurovascular solutions.

Limited Revenue Scale Currently generating between zero and one million dollars in revenue, Neuravi is a relatively small firm, indicating open opportunities to introduce complementary products, expand sales channels, or provide targeted solutions to accelerate their growth trajectory in neurovascular markets.

Regional Market Presence Headquartered in Galway, Ireland with active operations in Europe, there is a clear entry point for sales efforts focusing on European healthcare providers and hospitals seeking innovative stroke treatment devices, especially given the company’s focus on improving clinical outcomes for stroke patients.